Literature DB >> 22487537

Immunohistochemical expression of Annexin A2 and S100A proteins in patients with bulky stage IB-IIA cervical cancer treated with neoadjuvant chemotherapy.

LanYing Jin1, Qi Shen, Shengdi Ding, Wenxiao Jiang, Lingling Jiang, Xueqiong Zhu.   

Abstract

OBJECTIVE: Abnormal expression of Annexin A2 and S100A proteins has been reported to induce sensitivity/resistance to chemotherapy in a variety of cancers. The aim of this study was to evaluate the significance of Annexin A2 and S100A protein expression to predict response to neoadjuvant chemotherapy and prognostic significance of these protein expressions in bulky stage IB-IIA cervical cancer patients.
METHODS: Paired tumor samples (pre- and post-chemotherapy) were obtained from 68 patients who were treated with cisplatin-based neoadjuvant chemotherapy and radical hysterectomy at our hospital from 2006 to 2011. The expression of Annexin A2 and S100A proteins was analyzed by immunohistochemistry.
RESULTS: Thirty-six patients were identified as chemotherapy-response and 32 were non-response. (a). Protein expression in tumor cells: (1). Exposure of tumor cells to chemotherapy results in a change of Annexin A2 and S100A expression (P<0.05). (2). Annexin A2, S100A8 and S100A9 protein expression correlates with tumor response to chemotherapy (P<0.05). (b). Protein expression in stromal cells: (1). Expression of Annexin A2, S100A8 and S100A9 was increased, but S100A2 and S100A4 was decreased after exposure to chemotherapy (P<0.05). (2). Only S100A4 expression was associated with response to chemotherapy (P<0.05). Multivariate analysis revealed that tumor size (P=0.022), differentiation (P=0.000), Annexin A2 expression in stromal cells (P=0.009), and S100A8 expression in tumor cells (P=0.008) were independent prognostic factors for progression-free survival of cervical cancer patients.
CONCLUSIONS: Expression of some of the measured proteins in tumor and stromal cells correlates with chemotherapy exposure, response to therapy, and progression-free survival.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22487537     DOI: 10.1016/j.ygyno.2012.04.005

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  16 in total

1.  MicroRNA-335 represents an independent prognostic marker in cervical cancer.

Authors:  Changhe Wang; Tao Jiang
Journal:  Tumour Biol       Date:  2015-02-25

2.  A Novel TGFβ Trap Blocks Chemotherapeutics-Induced TGFβ1 Signaling and Enhances Their Anticancer Activity in Gynecologic Cancers.

Authors:  Haiyan Zhu; Xiang Gu; Lu Xia; You Zhou; Hakim Bouamar; Junhua Yang; Xiaofei Ding; Christian Zwieb; Jianan Zhang; Andrew P Hinck; Lu-Zhe Sun; Xueqiong Zhu
Journal:  Clin Cancer Res       Date:  2018-03-16       Impact factor: 12.531

3.  Correlation between the expression of S100A4 and the efficacy of TAC neoadjuvant chemotherapy in breast cancer.

Authors:  Wen-Lei Li; Yang Zhang; Bao-Guo Liu; Qian DU; Chang-Xin Zhou; Xing-Song Tian
Journal:  Exp Ther Med       Date:  2015-09-11       Impact factor: 2.447

4.  Potential serum biomarkers for glioblastoma diagnostic assessed by proteomic approaches.

Authors:  Ionela Daniela Popescu; Elena Codrici; Lucian Albulescu; Simona Mihai; Ana-Maria Enciu; Radu Albulescu; Cristiana Pistol Tanase
Journal:  Proteome Sci       Date:  2014-09-24       Impact factor: 2.480

5.  URG4 overexpression is correlated with cervical cancer progression and poor prognosis in patients with early-stage cervical cancer.

Authors:  Lan Zhang; He Huang; Longjuan Zhang; Teng Hou; Shu Wu; Qidan Huang; Libing Song; Jihong Liu
Journal:  BMC Cancer       Date:  2014-11-26       Impact factor: 4.430

6.  Prognostic significance of annexin A2 and annexin A4 expression in patients with cervical cancer.

Authors:  Chel Hun Choi; Joon-Yong Chung; Eun Joo Chung; John D Sears; Jeong-Won Lee; Duk-Soo Bae; Stephen M Hewitt
Journal:  BMC Cancer       Date:  2016-07-11       Impact factor: 4.430

7.  Overexpression of the S100A2 protein as a prognostic marker for patients with stage II and III colorectal cancer.

Authors:  Taiki Masuda; Toshiaki Ishikawa; Kaoru Mogushi; Satoshi Okazaki; Megumi Ishiguro; Satoru Iida; Hiroshi Mizushima; Hiroshi Tanaka; Hiroyuki Uetake; Kenichi Sugihara
Journal:  Int J Oncol       Date:  2016-01-11       Impact factor: 5.650

Review 8.  Molecular mechanisms of cisplatin resistance in cervical cancer.

Authors:  Haiyan Zhu; Hui Luo; Wenwen Zhang; Zhaojun Shen; Xiaoli Hu; Xueqiong Zhu
Journal:  Drug Des Devel Ther       Date:  2016-06-07       Impact factor: 4.162

Review 9.  Annexin A2: its molecular regulation and cellular expression in cancer development.

Authors:  Chi-Yun Wang; Chiou-Feng Lin
Journal:  Dis Markers       Date:  2014-01-23       Impact factor: 3.434

10.  PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer.

Authors:  Haiyan Zhu; Jun Wu; Wenwen Zhang; Hui Luo; Zhaojun Shen; Huihui Cheng; Xueqiong Zhu
Journal:  Sci Rep       Date:  2016-08-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.